
A new network meta-analysis of 29 RCTs reveals that combining standard therapy with GLP-1 receptor agonists significantly improves metabolic outcomes in women with PCOS, reducing weight, BMI, and insulin resistance. Orlistat effectively lowers testosterone and boosts HDL-C levels. These findings highlight the benefits of combination pharmacotherapy for better PCOS management.
Like
Save
Share